Thomas Kaleekal
Critical Care Medicine · Birmingham, ALNPI 1699765420
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 18 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by Actelion Pharmaceuticals US, Inc. at 45.0% of the total. Reporting peaked in 2020 at $163 and has fallen 88.1% since, to $19 in 2021. That places this record below the midpoint for critical care medicine clinicians in AL, where the typical reported total is $297.
Across 18 payments — averaging $16.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Actelion Pharmaceuticals US, Inc.$134
- Akcea Therapeutics, Inc.$28
- AbbVie$27
- Ambu Inc.$19
- Atricure, Inc.$18
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$15
- plus $56 from 4 others
What the payments were for
- Food & beverage$297100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Actelion Pharmaceuticals US, Inc. | 7 | $134 |
| Akcea Therapeutics, Inc. | 2 | $28 |
| AbbVie | 2 | $27 |
| Ambu Inc. | 1 | $19 |
| Atricure, Inc. | 1 | $18 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $15 |
| Shire North American Group Inc | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| Astellas Pharma US Inc | 1 | $14 |
| Amarin Pharma, Inc. | 1 | $13 |
How this compares
$297 in reported general payments places this provider in the 50th percentile of 73 critical care medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 41 | $246,496 |
| EliquisApixaban | 17 | $16,864 |
| Itraconazole | 12 | $5,479 |
| Valganciclovir Hcl | 25 | $4,167 |
| Dapsone | 25 | $4,020 |
| Tacrolimus | 14 | $3,406 |
| Mycophenolate Mofetil | 27 | $2,062 |
| Azithromycin | 40 | $674 |
| Prednisone | 90 | $600 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 43 | $430 |
| Pantoprazole Sodium | 30 | $391 |
| Metoprolol Tartrate | 43 | $298 |
| Levothyroxine Sodium | 15 | $290 |
| Acyclovir | 26 | $248 |
| Amlodipine Besylate | 14 | $240 |
Paid to pharmacies, not to this prescriber.
Other critical care medicine in Birmingham
- James WellsBirmingham$223K
- Mark DransfieldBirmingham$160K
- George SolomonBirmingham$113K
- Tracy LuckhardtBirmingham$28K
- Keith WilleBirmingham$9K
- Victor ThannickalBirmingham$8K
- Vipul ShahBirmingham$6K
- Samuel McElweeBirmingham$5K
- Nicole SchreinerBirmingham$4K
- David LafonBirmingham$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.